AstraZeneca PLC (LSE:AZN) agreed to acquire Amolyt Pharma SAS for $1.05 billion on March 14, 2024. Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma?s outstanding shares for a total consideration of up to $1.05B, on a cash and debt free basis. This includes $800 million upfront at deal closing, plus the right for Amolyt Pharma?s shareholders to receive an additional contingent payment of $250 million payable upon achievement of a specified regulatory milestone. Subject to the satisfaction of customary closing conditions in the acquisition agreement, including regulatory clearances, the transaction is expected to close by the end of the third quarter of 2024. Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Geoffroy Pineau-Valencienne of Jones Day acted as legal counsels for Amolyt and its shareholders.

AstraZeneca PLC (LSE:AZN) completed the acquisition of Amolyt Pharma SAS on July 15, 2024.